Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
The involvement of the dopamine reward pathway in modulating food and alcohol consumption 15 could explain why semaglutide is beneficial in reducing food consumption 16 and in animal models reducing alcohol and other drug consumption 5
-synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinsons disease from multiple system atrophy
Of 302 volunteers, only 108 met the eligibility criteria
Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z et al
TrimRx $349/month pricing includes everything with no hidden fees or additional charges
